Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000204908 | SCV000259478 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2023-02-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser564*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 27601186). ClinVar contains an entry for this variant (Variation ID: 219551). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV000481005 | SCV000570637 | pathogenic | not provided | 2017-04-14 | criteria provided, single submitter | clinical testing | This variant is denoted MSH6 c.1691C>A at the cDNA level and p.Ser564Ter (S564X) at the protein level. The substitution creates a nonsense variant, which changes a Serine to a premature stop codon (TCA>TAA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been observed in an individual tested on a hereditary colorectal cancer panel (Ferber 2016). We consider this variant to be pathogenic. |
Ambry Genetics | RCV000491176 | SCV000580348 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-10-28 | criteria provided, single submitter | clinical testing | The p.S564* pathogenic mutation (also known as c.1691C>A), located in coding exon 4 of the MSH6 gene, results from a C to A substitution at nucleotide position 1691. This changes the amino acid from a serine to a stop codon within coding exon 4. This mutation has been detected in multiple endometrial cancer patients whose tumors demonstrated loss of MSH6 on immunohistochemistry (Ambry internal data). A different nucleotide change at this position (c.1691C>G) that leads to the same stop codon was seen in two Swedish families with Lynch syndrome (Lagerstedt-Robinson K et al. Oncol. Rep., 2016 Nov;36:2823-2835). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Counsyl | RCV000576302 | SCV000677830 | likely pathogenic | Lynch syndrome 5 | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000491176 | SCV000690217 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-10-01 | criteria provided, single submitter | clinical testing | This variant changes 1 nucleotide in exon 4 of the MSH6 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been observed in an individual affected with ovarian cancer (Color internal data). A different DNA substitution resulting in the same protein consequence (c.1691C>G; p.Ser564*) has been observed in two families affected with Lynch syndrome (PMID: 27601186). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000481005 | SCV000888247 | pathogenic | not provided | 2018-01-16 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000576302 | SCV004018900 | pathogenic | Lynch syndrome 5 | 2023-03-28 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Prevention |
RCV004530217 | SCV004121047 | pathogenic | MSH6-related disorder | 2022-09-21 | criteria provided, single submitter | clinical testing | The MSH6 c.1691C>A variant is predicted to result in premature protein termination (p.Ser564*). This variant has been reported in an individual being tested on a hereditary colorectal cancer panel (Ferber et al. 2016. Journal of Medical Diagnostic Methods, vol 5). A different nucleotide variant (c.1691C>G) which also causes a premature termination codon at this position has been reported in individuals with Lynch syndrome (Lagerstedt-Robinson et al. 2016. PubMed ID: 27601186). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in MSH6 are expected to be pathogenic. Given the evidence, we interpret c.1691C>A (p.Ser564*) as pathogenic. |
CZECANCA consortium | RCV001270947 | SCV001451751 | pathogenic | Breast and/or ovarian cancer | 2019-06-11 | no assertion criteria provided | clinical testing |